Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9 IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9 IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Sodium chloride 0.9% is an isotonic crystalloid solution that increases intravascular volume by replacing extracellular fluid and electrolytes. It does not have a specific molecular target; its primary pharmacological effect is osmotic expansion of the vascular compartment.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous injection of 10 mL of 0.9% sodium chloride solution for cardiac output determination via thermodilution, repeated as needed every 3-5 minutes for up to 3 injections per measurement set.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Not applicable as a conventional drug; sodium and chloride are endogenous electrolytes. The infused ions are distributed and eliminated according to body homeostasis. The plasma half-life of an infused sodium load is approximately 30-60 minutes in euvolemic individuals, but is highly variable based on renal function and volume status.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Primarily renal (>95%). Sodium and chloride ions are freely filtered at the glomerulus and undergo variable tubular reabsorption depending on volume status; excess is excreted unchanged in urine. Fecal and biliary elimination are negligible.
Category C
Category A/B
Electrolyte
Electrolyte